StocksFundsScreenerSectorsWatchlists
PAHC

PAHC - Phibro Animal Health Corp Stock Price, Fair Value and News

13.10USD+0.04 (+0.31%)Delayed as of 28 Mar 2024, 03:01 pm ET

Market Summary

PAHC
USD13.10+0.04
Delayedas of 28 Mar 2024, 03:01 pm
0.31%

PAHC Alerts

  • Big fall in earnings (Y/Y)

PAHC Stock Price

View Fullscreen

PAHC RSI Chart

PAHC Valuation

Market Cap

529.0M

Price/Earnings (Trailing)

30.24

Price/Sales (Trailing)

0.54

EV/EBITDA

10.93

Price/Free Cashflow

7.12

PAHC Price/Sales (Trailing)

PAHC Profitability

EBT Margin

2.86%

Return on Equity

6.46%

Return on Assets

1.8%

Free Cashflow Yield

14.04%

PAHC Fundamentals

PAHC Revenue

Revenue (TTM)

982.0M

Rev. Growth (Yr)

2.17%

Rev. Growth (Qtr)

8.04%

PAHC Earnings

Earnings (TTM)

17.5M

Earnings Growth (Yr)

-82.33%

Earnings Growth (Qtr)

127.33%

Breaking Down PAHC Revenue

52 Week Range

12.1315.98
(Low)(High)

Last 7 days

-2.0%

Last 30 days

0.2%

Last 90 days

7.9%

Trailing 12 Months

-19.3%

How does PAHC drawdown profile look like?

PAHC Financial Health

Current Ratio

3.12

Debt/Equity

0.8

Debt/Cashflow

0.34

PAHC Investor Care

Dividend Yield

3.68%

Dividend/Share (TTM)

0.48

Diluted EPS (TTM)

0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023978.1M977.9M976.7M982.0M
2022907.3M942.3M960.1M972.1M
2021799.0M833.4M852.8M879.4M
2020818.4M800.4M805.8M798.0M
2019835.9M828.0M817.6M813.4M
2018803.0M820.0M826.7M839.1M
2017758.6M764.3M769.7M784.0M
2016747.3M751.5M752.4M752.2M
2015747.3M748.6M748.3M751.3M
2014672.4M691.9M717.1M733.1M
2013653.4M653.2M653.3M661.9M
20120654.1M653.9M653.6M

Tracking the Latest Insider Buys and Sells of Phibro Animal Health Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 30, 2021
corcoran e thomas
bought
118,400
23.68
5,000
-
Feb 09, 2021
miller larry lee
sold
-458,812
22.9406
-20,000
chief operating officer
Feb 08, 2021
miller larry lee
acquired
-
-
50,000
chief operating officer
Aug 30, 2019
corcoran e thomas
bought
106,050
21.21
5,000
-
Jan 30, 2019
bendheim daniel m
acquired
28,273
11.83
2,390
exec. vp, corporate strategy
Jan 30, 2019
bendheim daniel m
sold
-74,448
31.15
-2,390
exec. vp, corporate strategy
Jan 29, 2019
bendheim daniel m
acquired
57,848
11.83
4,890
exec. vp, corporate strategy
Jan 29, 2019
bendheim daniel m
sold
-153,155
31.32
-4,890
exec. vp, corporate strategy
Jan 28, 2019
bendheim daniel m
acquired
29,575
11.83
2,500
exec. vp, corporate strategy
Jan 28, 2019
bendheim daniel m
sold
-78,875
31.55
-2,500
exec. vp, corporate strategy

1–10 of 34

Which funds bought or sold PAHC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-58.02
-18,089
11,116
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-19.85
-7,830,810
20,830,300
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
155
2,573,380
4,522,890
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.83
-14,424
128,804
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-6,000
66,000
-%
Feb 20, 2024
Quarry LP
new
-
13,468
13,468
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.12
-14,000
166,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-0.1
-99,000
944,000
0.08%
Feb 15, 2024
BARCLAYS PLC
added
73.44
260,000
716,000
-%
Feb 15, 2024
Virtus Investment Advisers, Inc.
unchanged
-
-27,065
263,376
0.20%

1–10 of 49

Are Funds Buying or Selling PAHC?

Are funds buying PAHC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PAHC
No. of Funds

Unveiling Phibro Animal Health Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
bfi co., llc
49.9%
20,225,514
SC 13D/A
Feb 13, 2024
vanguard group inc
8.84%
1,798,821
SC 13G/A
Feb 08, 2024
pzena investment management llc
9.8%
1,989,558
SC 13G
Jan 19, 2024
blackrock inc.
18.0%
3,667,385
SC 13G/A
Jan 10, 2024
brandes investment partners, lp
10.48%
2,131,064
SC 13G
Dec 08, 2023
brandes investment partners, lp
10.03%
2,040,380
SC 13G
Jun 08, 2023
bfi co., llc
49.9%
20,225,514
SC 13D/A
Mar 07, 2023
pzena investment management llc
10.04%
2,042,114
SC 13G/A
Feb 13, 2023
fiduciary management inc /wi/
12.%
-
SC 13G
Feb 09, 2023
vanguard group inc
11.62%
2,362,803
SC 13G/A

Recent SEC filings of Phibro Animal Health Corp

View All Filings
Date Filed Form Type Document
Mar 05, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
SC 13D/A
13D - Major Acquisition
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
3
Insider Trading
Feb 08, 2024
SC 13G
Major Ownership Report
Feb 07, 2024
8-K
Current Report
Feb 07, 2024
10-Q
Quarterly Report
Feb 06, 2024
8-K
Current Report
Feb 06, 2024
8-K
Current Report

What is the Fair Value of PAHC?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Phibro Animal Health Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
380.6B
85.2B
-0.84% 1.87%
10.83
4.47
6.46% 95.94%
333.8B
60.1B
-3.08% 18.97%
914.53
5.55
1.40% -97.49%
156.9B
46.5B
-0.94% -29.07%
-113.02
3.37
42.59% -114.62%
153.4B
28.2B
-2.65% 20.18%
22.84
5.44
7.09% 2.52%
91.0B
27.1B
1.44% -6.08%
16.06
3.35
-0.60% 23.36%
16.2B
15.8B
6.68% 47.26%
-28.08
1.02
6.17% 76.47%
MID-CAP
4.6B
1.7B
-15.20% 8.04%
12.8
2.74
49.61% 324.78%
4.3B
4.7B
-2.22% -15.29%
-335.7
0.92
4.58% 90.97%
3.8B
8.8B
12.34% 25.79%
-6.47
0.44
7.79% -163.11%
2.1B
644.4M
-19.16% 20.49%
15.22
3.25
29.14% 50.51%
SMALL-CAP
1.8B
700.5M
20.31% -
-1.29
2.63
16.26% -147.49%
24.2M
70.0M
1.33% -38.14%
0.35
0.34
-19.54% 888.31%
18.7M
-
-10.40% 69.70%
-1.01
0.22
2882.68% -138.52%
14.8M
111.1M
-18.24% -6.20%
-0.93
0.13
-10.43% 84.90%
929.3K
20.0M
-54.17% -94.76%
-0.07
0.05
137.71% 66.04%

Phibro Animal Health Corp News

Latest updates
Defense World • 11 hours ago
Yahoo Finance • 22 Mar 2024 • 12:33 pm
Yahoo Finance • 18 Mar 2024 • 07:00 am

Phibro Animal Health Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue8.0%250231255246245233255240233215220212206195186211214190204206218
Gross Profit16.1%79.0068.0077.0076.0077.0069.0078.0072.0071.0065.0070.0069.0068.0064.0061.0070.0069.0058.0065.0065.0069.00
  S&GA Expenses-8.1%63.0068.0053.0057.0062.0055.0056.0052.0048.0050.0051.0049.0048.0048.0042.0048.0049.0048.0053.0042.0043.00
EBITDA Margin-16.9%0.05*0.06*0.07*0.07*0.08*0.09*0.10*0.11*0.10*0.09*0.10*0.11*0.11*0.11*0.09*0.08*0.08*0.08*0.11*0.12*0.13*
Interest Expenses-2.1%-4.66-4.56-4.50-3.87-3.88-3.07-3.11-2.92-2.95-2.89-3.92-2.93-3.21-2.81-2.81-3.26-3.43-3.35-3.05-2.93-3.01
Income Taxes157.8%2.00-3.9610.005.005.002.005.009.006.003.00-1.006.003.004.0011.005.005.001.000.005.005.00
Earnings Before Taxes129.8%4.00-11.9821.0015.0012.005.0012.0027.0024.0010.0016.0018.0016.0017.0016.0019.0017.004.009.0020.0020.00
EBT Margin-23.7%0.03*0.04*0.06*0.05*0.06*0.07*0.08*0.08*0.08*0.07*0.08*0.08*0.08*0.08*0.07*0.06*0.06*0.06*0.09*0.10*0.11*
Net Income127.3%1.00-4.6611.0010.007.005.0014.0018.0011.00-0.3613.0012.0025.008.008.0014.0015.00-5.0311.0015.0017.00
Net Income Margin-25.7%0.02*0.02*0.04*0.04*0.05*0.05*0.05*0.05*0.04*0.06*0.07*0.07*0.07*0.06*0.04*0.04*0.04*0.05*0.06*0.08*0.08*
Free Cashflow94.8%32.0016.0020.006.00-2.49-10.702.006.0020.004.003.0017.0027.002.004.0027.0032.00-3.5715.0016.0015.00
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.8%973965971965962948932916849836841805804790784776788795727706697
  Current Assets0.4%587584586585582570566546509499499472477464452438445456466452441
    Cash Equivalents-23.6%33.0043.0041.0037.0068.0076.0074.0071.0063.0041.0050.0049.0035.0031.0036.0027.0026.0055.0058.0036.0031.00
  Inventory2.7%287279278293289281259250231221216206213206197177194204198190193
  Net PPE3.9%201193196189186179165162155153155150150147148143145142140135133
  Goodwill2.7%55.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0053.0027.0027.0027.00
Liabilities1.5%702691689693693686669649610603603589590597596581571589511493492
  Current Liabilities8.9%188172176165168172191187167153164169167161157161147142154133136
  Long Term Debt-------------------218221224
Shareholder's Equity-0.8%271273283272268263262267239233239216213192188195217207216214205
  Retained Earnings-1.4%244248261254249247248245232220218206198191183182174167169165155
  Additional Paid-In Capital0.1%136136136136136136136136136136136137137136136135134134133133131
Shares Outstanding0%41.0041.0041.0041.0041.0041.0041.0041.0041.0041.0040.0040.0040.0040.0040.0040.0040.0040.00-40.0040.00
Float-----272---414---393---502---648
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations94.8%31,55816,19920,2386,259-2,489-10,6981,5746,13220,1223,8213,07016,62526,9131,6983,87726,95032,091-3,57014,87915,65415,356
  Share Based Compensation-1.2%80.0081.00----------564565565565564565565565564
Cashflow From Investing-61.9%-24,861-15,352-10,282-37,777-9,810-16,149-9,540-9,94417,568-20,666-7,1909,869-7,624-13,635-9,533-14,148-34,178-62,53114,743-7,948-4,779
Cashflow From Financing-1234.6%-14,7051,296-6,3322843,71629,31912,38910,265-14,5768,2654,637-11,548-16,5426,45814,985-10,979-27,00163,931-7,999-2,982-4,860
  Dividend Payments0.0%4,8614,8604,8614,8614,8604,8604,8614,8604,8614,8604,8614,8604,8554,8544,8554,8544,8554,8544,8544,8554,846

PAHC Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net sales$ 249,943$ 244,646$ 481,292$ 477,167
Cost of goods sold171,327167,261334,950331,136
Gross profit78,61677,385146,342146,031
Selling, general and administrative expenses62,91561,541131,367116,503
Operating income15,70115,84414,97529,528
Interest expense, net4,6593,8849,2236,951
Foreign currency losses (gains), net7,477(149)14,1665,051
Income (loss) before income taxes3,56512,109(8,414)17,526
Provision (benefit) for income taxes2,2914,899(1,673)6,460
Net income (loss)$ 1,274$ 7,210$ (6,741)$ 11,066
Net income (loss) per share    
basic (in dollars per share)$ 0.03$ 0.18$ (0.17)$ 0.27
diluted (in dollars per share)$ 0.03$ 0.18$ (0.17)$ 0.27
Weighted average common shares outstanding    
basic (in shares)40,50440,50440,50440,504
diluted (in shares)40,50440,50440,50440,504

PAHC Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
ASSETS  
Cash and cash equivalents$ 32,970$ 41,281
Short-term investments59,52340,000
Accounts receivable, net150,627163,479
Inventories, net286,680277,570
Other current assets56,78663,393
Total current assets586,586585,723
Property, plant and equipment, net200,839195,568
Intangibles, net50,96254,987
Goodwill54,68353,274
Other assets79,63881,845
Total assets972,708971,397
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current portion of long-term debt26,04522,295
Accounts payable86,41073,853
Accrued expenses and other current liabilities75,28079,852
Total current liabilities187,735176,000
Revolving credit facility151,000141,000
Long-term debt297,853311,541
Other liabilities65,31760,347
Total liabilities701,905688,888
Commitments and contingencies (Note 8)
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at December 31, 2023, and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at December 31, 2023, and June 30, 202344
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding
Paid-in capital135,964135,803
Retained earnings244,450260,912
Accumulated other comprehensive loss(109,615)(114,210)
Total stockholders' equity270,803282,509
Total liabilities and stockholders' equity$ 972,708$ 971,397
PAHC
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
 CEO
 WEBSITEwww.pahc.com
 EMPLOYEES1920

Phibro Animal Health Corp Frequently Asked Questions


What is the ticker symbol for Phibro Animal Health Corp? What does PAHC stand for in stocks?

PAHC is the stock ticker symbol of Phibro Animal Health Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phibro Animal Health Corp (PAHC)?

As of Wed Mar 27 2024, market cap of Phibro Animal Health Corp is 528.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PAHC stock?

You can check PAHC's fair value in chart for subscribers.

What is the fair value of PAHC stock?

You can check PAHC's fair value in chart for subscribers. The fair value of Phibro Animal Health Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Phibro Animal Health Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PAHC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Phibro Animal Health Corp a good stock to buy?

The fair value guage provides a quick view whether PAHC is over valued or under valued. Whether Phibro Animal Health Corp is cheap or expensive depends on the assumptions which impact Phibro Animal Health Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PAHC.

What is Phibro Animal Health Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, PAHC's PE ratio (Price to Earnings) is 30.24 and Price to Sales (PS) ratio is 0.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PAHC PE ratio will change depending on the future growth rate expectations of investors.